Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults with Acute Myeloid Leukemia

Therapeutic Drug Monitoring

Volumn 37, Issue 4, 2015, Pages 508-511

  Hummert, Shelly E ^a   Green, Myke R ^b,c  

^a PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^b UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

antifungal; posaconazole; prophylaxis; therapeutic drug monitoring

Indexed keywords

POSACONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; BLOOD; DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TRIAZOLES;

EID: 84937839131     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000175     Document Type: Article

References (10)

1. Cannas G, Pautas C, Raffoux E, et al. Infectious complications in adult acute myeloid leukemia: an analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial. Leuk Lymphoma. 2012;53:1068-1076.
2. Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses. 2013;56: 638-645.
3. Frampton JE, Scott LJ. Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs. 2008;68:993-1016.
4. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359.
5. Vehreschild JJ, Ruping MJGT, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65:1466-1471.
6. Pechlivanoglou P, Le HH, Daenen S, et al. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review. J Antimicrob Chemother. 2014;69:1-11.
7. Jang SH, Colangelo PM, Gobburu JVS. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. 2010;88:115-119.
8. Dolton MJ, Ray JE, Marriott D, et al. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother. 2012;56:2806-2813.
9. Hoenigl M, Raggam RB, Salzer HJF, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents. 2012;39:510-513.
10. Green MR, Woolery JE. Optimising absorption of posaconazole. Mycoses. 2011;54:e775-e779.